Clinical trials: Acute Graft Rejection
Cardiac Transplant Rejection
The "no Biopsy Approach" for Heart Transplantation Follow-up
Pathological analysis is the gold standard for diagnosis of acute allograft rejection after heart transplantation (HTx). This method requires repeated endomyocardial biopsies during the first post-operative year.
- Trial name
- NCT03959579
- Testing
- systematic endomyocardial biopsy.
- Where
- France
- Volunteers
- 269 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Heart Transplant Rejection
Research on Patients With Heart Transplantation
This trial was a single-center, prospective cohort study.The purpose of this clinical research is to evaluate the accuracy of combining multimodality MR Imaging with circulating exosomal miRNA expression to diagnose acute…
- Trial name
- NCT04921774
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangdong Provincial People's Hospital
Kidney Transplant Rejection, Pediatric Kidney Disease
Pediatric Induction Therapy in Kidney Transplantation
The goal of this observational study is to compare the efficacy of two most commonly used induction therapy for the prevention of acute rejection (AR) after renal transplantation in children.
- Trial name
- PINK (NCT06087003)
- Testing
- Basiliximab Injection, rabbit ATG
- Where
- 5 sites in China
- Volunteers
- 958 people
- Sponsor
- Gang Chen
Acute Leukemia
Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation
The purpose of this study is to evaluate the safety and efficacy of PROMOSTEM (human umbilical cord blood-derived mesenchymal stem cells) at a dose of 1 and 5x1,000,000 hMSC/kg in subject for the promotion of an engraftment and…
- Trial name
- NCT00823316
- Testing
- Human umbilical cord blood-derived mesenchymal stem cells
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Medipost Co Ltd.
Posttransplant Diabetes Mellitus, Acute Graft Rejection
Silymarin's Advantage on Graft Effectiveness
The study examines the impact of silymarin supplementation during the early post-transplant period, administering 900 g daily for 30 days under standard treatment.
- Conditions
- Posttransplant Diabetes Mellitus, Acute Graft Rejection, Biopsy Proven Acute Rejection, Antibody Mediated Rejection of Kidney Transplant
- Trial name
- SAGE (NCT06801886)
- Testing
- Silymarine supplementation
- Where
- Slovakia
- Volunteers
- 130 people
- Sponsor
- University Hospital, Martin
Complication of Transplanted Liver
Donor Specific HLA Alloantibodies in Liver Transplantation
The aim is to evaluate the impact of donor specific HLA alloantibodies (DSA) on all-cause mortality and re-transplantation, early allograft dysfunction, acute and chronic rejection, fibrosis, vascular, and biliary complications.
- Trial name
- NCT02784080
- Testing
- HLA-alloantibodies exposure
- Where
- 5 sites in Denmark, Finland and 2 more
- Volunteers
- 858 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Lung Transplant Rejection
Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients
Background/Rationale Acute rejection (AR) is common in the first year after lung transplantation. AR has usually been reversible with treatment, but it can trigger chronic rejection that is the leading causes of late morbidity…
- Trial name
- PHORLUCY (NCT03500575)
- Testing
- photopheresis
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Hematologic Malignancies, Bone Marrow Transplant Rejection
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor's T cells (a type of lymphocyte, or white blood cell) are removed and then added back.
- Trial name
- NCT00079391
- Testing
- allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Kidney Transplantation, Acute Graft Rejection
Pre-formed Alloreactivity in Renal Transplant Recipients
This investigator-initiated study will analyse the role of pre-formed alloreactive T cells on acute rejection episodes and graft outcome in kidney transplant recipients after living donation.
- Trial name
- NCT02633826
- Where
- 13 sites in Germany
- Volunteers
- 190 people
- Sponsor
- Martina Sester
Kidney Transplantation
Rituximab for Pediatric Renal Transplant Rejection
Rituximab will be tested for its safety and potential efficacy in treating B cell dense renal allograft rejection episodes in children receiving renal transplants at Stanford University
- Trial name
- NCT00697996
- Testing
- Rituximab for transplant rejection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Kidney Transplant Rejection
Tacrolimus Exposure in Kidney Transplantation
Using CDW data from 5 tertiary hospitals in Korea, this study identify the optimal range of trough level that can prevent adverse outcome in the early periods after transplantation.
- Trial name
- NCT06348446
- Where
- 4 sites in South Korea
- Volunteers
- 12,000 people
- Sponsor
- Seoul National University Hospital
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
This phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00096161
- Testing
- Cyclosporine, Mycophenolate Mofetil, Pentostatin
- Where
- 5 sites in United States, Italy
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Lung Transplant Rejection, Primary Graft Dysfunction
Exhaled Breath Particles in Lung Transplantation
Lung transplantation (LTx) is the only effective treatment for patients with end stage lung disease. Of the major organs transplanted, survival following LTx is the lowest with a mean of 5 years.
- Conditions
- Lung Transplant Rejection, Primary Graft Dysfunction, Chronic Rejection of Lung Transplant
- Trial name
- NCT05375149
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Lund University Hospital
Acute Liver Failure, Acute-On-Chronic Liver Failure
Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.
Efficient immunosuppressive therapy and improved surgical techniques have developed liver transplantation as a well-established and life-saving treatment. The 1-year survival rate of approximately 85-90%.
- Conditions
- Acute Liver Failure, Acute-On-Chronic Liver Failure, Liver Cirrhosis
- Trial name
- NCT04621812
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients
The purpose of this study is to determine if everolimus combined with reduced exposure CNI (TAC) is efficacious and safe and will support corticosteroid elimination compared to a standard exposure CNI (TAC) + MMF + steroid…
- Trial name
- NCT01544491
- Testing
- RAD001, MMF
- Where
- 31 sites in United States, Argentina and 11 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Renal Failure, Chronic
Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection
Chronic transplant rejection remains the main cause of late kidney graft loss. We showed previously that patients with pretransplant CD4 helper defects and low in-vitro IL-10 responses demonstrated an extremely low risk of acute…
- Trial name
- NCT00150891
- Testing
- Kidney transplantation, cyclosporine A, tacrolimus
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- University of Giessen
Cardiovascular Disease, Acute Rejection of Cardiac Transplant
Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)
The primary goal of this Multicenter Study is to develop and to evaluate a method for measuring donor-specific cell free DNA in blood samples from transplant recipients as markers of rejection.
- Conditions
- Cardiovascular Disease, Acute Rejection of Cardiac Transplant, Cardiac Transplant Rejection, Heart Transplant Failure and Rejection
- Trial name
- DTRT (NCT02109575)
- Testing
- Blood Draw of up to 10 ml
- Where
- 8 sites in United States
- Volunteers
- 540 people
- Sponsor
- Medical College of Wisconsin
Acute Graft Rejection, Chronic Allograft Nephropathy
Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation
After alemtuzumab induction, followed with kidney transplantation, patients will be randomly assigned to receive either tacrolimus or cyclosporine microemulsion in combination with mycophenolates.
- Conditions
- Acute Graft Rejection, Chronic Allograft Nephropathy, Polyomavirus-related Transplant Nephropathy
- Trial name
- RSCS-Campath (NCT01346397)
- Testing
- cyclosporine or tacrolimus
- Where
- Russia
- Volunteers
- 170 people
- Sponsor
- Russian Academy of Medical Sciences
Rejection Acute Renal, Rejection Chronic Renal
Extended Validation of Donor-derived Cell-free DNA in Kidney Transplant Recipients
This is a multinational, multi-center, observational cohort study. Kidney allograft rejection is poorly detected by standard-of-care biomarkers.
- Conditions
- Rejection Acute Renal, Rejection Chronic Renal, Transplantation, Kidney Rejection Transplant
- Trial name
- VALiDATE (NCT07805343)
- Testing
- Donor-derived cell-free DNA
- Where
- 25 sites in United States, Belgium and 6 more
- Volunteers
- 5,000 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Rejection; Transplant, Kidney, Rejection; Transplant, Pancreas
A Multicenter Randomized Controlled Trial to Treat Acute T Cell Mediated Rejection in Kidney and Kidney-Pancreas Transplant Recipients
After a kidney or a kidney-pancreas transplant, some patients may face problems with their new organs. This happens because the body sometimes makes a mistake and tries to get rid of the organ. This problem is called rejection.
- Trial name
- TACKLE-IT (NCT06474273)
- Testing
- Methylprednisolone, Prednisone
- Where
- 30 sites in Australia, Canada and 1 more
- Volunteers
- 540 people
- Sponsor
- University of Sydney